Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
Pain represents a primary symptom of numerous diseases and conditions, affecting millions of people worldwide. Effective analgesic medications can alleviate or eliminate pain, thereby enhancing patients’ quality of life and assisting them in resuming normal physical and social activities. However, several existing analgesics may carry unwanted side effects, such as ulcers, blood clotting issues, drowsiness, and more. The development of new analgesics is focused on creating drugs that are both effective and associated with fewer adverse effects. Considering the continuous rise in the number of patients dealing with neurological, oncological, and other conditions accompanied by chronic pain, there is a growing demand for innovative methods of treatment and pain management. The combination of two different heterocyclic fragments within one molecule makes it possible to use the possibilities of influencing such a molecule on various mechanisms of occurrence and development of various pathological conditions, including those accompanied by pain. Chemical modifications of pyrazole and 1,2,4-triazole structures, involving their incorporation into a single molecule, have the potential, as suggested by in silico predictions, to yield biologically active compounds with analgesic properties. The aim of this work was to determine the optimal conditions for the chemical transformation and properties of 4-amino-5-(3-methylpyrazol-5-yl)-1,2,4-triazole-3-thiol, 4-amino-5-(3-(3-fluorophenyl)pyrazol-5-yl)-1,2,4-triazole-3-thiol and their derivatives for the preparation of bioactive systems with analgesic activity. Materials and methods. The creation of a target series of compounds was implemented by consistently using well-known methods of organic synthesis. 4-Amino-5-(3-methylpyrazole-5-yl)-1,2,4-triazole-3-thiol and 4-amino-5-(3-(3-fluorophenyl)pyrazole-5-yl)-1,2,4-triazole-3-thiol were resynthesized as starting materials using acetone or 1-(3-fluorophenyl)ethane-1-one, diethyloxalate, and sodium methylate using step-by-step hydrazinolysis and carbon disulfide involvement in an alkaline medium. Further targeted functionalization involved the introduction of a 2,6-dichlorophenyl substitute, alkane acid residues, and esters based on them into the structure of the target compounds. The structure of all synthesized substances was determined by IR spectrophotometry, 1H NMR spectroscopy, and elemental analysis. The individuality of the compounds was confirmed by high-performance liquid chromatography-mass spectrometry. The analgesic properties were studied on two models: the “acetic acid-induced writhing test” and a formalin model of pain inflammation. Pharmacokinetic parameters were predictably calculated using the SwissADME online platform. Results. Based on the results of the synthetic part of the work, the structure of 4-amino-5-(3-methylpyrazole-5-yl)-1,2,4-triazole-3-thiol and 4-amino-5-(3-(3-fluorophenyl)pyrazole-5-yl)-1,2,4-triazole-3-thiol, as well as their derivatives, was successfully recreated. The presence of a beneficial effect of 2,6-dichlorophenyl substitute, as well as fragments of saturated carboxylic acids and their esters on the formation of antinociceptive activity has been proven. The quantitative indicators of pharmacokinetic parameters, as determined during ADME analysis, fall within acceptable ranges in nearly all instances. Conclusions. The optimal conditions for the synthesis and structural modification of 4-amino-5-(3-methylpyrazol-5-yl)-1,2,4-triazole-3-thiol, 4-amino-5-(3-(3-fluorophenyl)pyrazol-5-yl)-1,2,4-triazole-3-thiol were established, which allowed the preparation of 2-((4-amino-5-(3-methylpyrazol-5-yl)-1,2,4-triazol-3-yl)thio)alkanoic acids and their esters, as well as [1,2,4]triazolo[3,4-b][1,3,4]thiadiazine systems. It has been shown that the combination of pyrazole derivatives of 1,2,4-triazol-3-thiol with 2,6-dichlorophenyl substituent and fragments of saturated carboxylic acids and their esters creates conditions for the formation of compounds with antinociceptive activity, which was confirmed in vivo by experimental data acetic acid-induced writhing test and formalin inflammation model.
Pain represents a primary symptom of numerous diseases and conditions, affecting millions of people worldwide. Effective analgesic medications can alleviate or eliminate pain, thereby enhancing patients’ quality of life and assisting them in resuming normal physical and social activities. However, several existing analgesics may carry unwanted side effects, such as ulcers, blood clotting issues, drowsiness, and more. The development of new analgesics is focused on creating drugs that are both effective and associated with fewer adverse effects. Considering the continuous rise in the number of patients dealing with neurological, oncological, and other conditions accompanied by chronic pain, there is a growing demand for innovative methods of treatment and pain management. The combination of two different heterocyclic fragments within one molecule makes it possible to use the possibilities of influencing such a molecule on various mechanisms of occurrence and development of various pathological conditions, including those accompanied by pain. Chemical modifications of pyrazole and 1,2,4-triazole structures, involving their incorporation into a single molecule, have the potential, as suggested by in silico predictions, to yield biologically active compounds with analgesic properties. The aim of this work was to determine the optimal conditions for the chemical transformation and properties of 4-amino-5-(3-methylpyrazol-5-yl)-1,2,4-triazole-3-thiol, 4-amino-5-(3-(3-fluorophenyl)pyrazol-5-yl)-1,2,4-triazole-3-thiol and their derivatives for the preparation of bioactive systems with analgesic activity. Materials and methods. The creation of a target series of compounds was implemented by consistently using well-known methods of organic synthesis. 4-Amino-5-(3-methylpyrazole-5-yl)-1,2,4-triazole-3-thiol and 4-amino-5-(3-(3-fluorophenyl)pyrazole-5-yl)-1,2,4-triazole-3-thiol were resynthesized as starting materials using acetone or 1-(3-fluorophenyl)ethane-1-one, diethyloxalate, and sodium methylate using step-by-step hydrazinolysis and carbon disulfide involvement in an alkaline medium. Further targeted functionalization involved the introduction of a 2,6-dichlorophenyl substitute, alkane acid residues, and esters based on them into the structure of the target compounds. The structure of all synthesized substances was determined by IR spectrophotometry, 1H NMR spectroscopy, and elemental analysis. The individuality of the compounds was confirmed by high-performance liquid chromatography-mass spectrometry. The analgesic properties were studied on two models: the “acetic acid-induced writhing test” and a formalin model of pain inflammation. Pharmacokinetic parameters were predictably calculated using the SwissADME online platform. Results. Based on the results of the synthetic part of the work, the structure of 4-amino-5-(3-methylpyrazole-5-yl)-1,2,4-triazole-3-thiol and 4-amino-5-(3-(3-fluorophenyl)pyrazole-5-yl)-1,2,4-triazole-3-thiol, as well as their derivatives, was successfully recreated. The presence of a beneficial effect of 2,6-dichlorophenyl substitute, as well as fragments of saturated carboxylic acids and their esters on the formation of antinociceptive activity has been proven. The quantitative indicators of pharmacokinetic parameters, as determined during ADME analysis, fall within acceptable ranges in nearly all instances. Conclusions. The optimal conditions for the synthesis and structural modification of 4-amino-5-(3-methylpyrazol-5-yl)-1,2,4-triazole-3-thiol, 4-amino-5-(3-(3-fluorophenyl)pyrazol-5-yl)-1,2,4-triazole-3-thiol were established, which allowed the preparation of 2-((4-amino-5-(3-methylpyrazol-5-yl)-1,2,4-triazol-3-yl)thio)alkanoic acids and their esters, as well as [1,2,4]triazolo[3,4-b][1,3,4]thiadiazine systems. It has been shown that the combination of pyrazole derivatives of 1,2,4-triazol-3-thiol with 2,6-dichlorophenyl substituent and fragments of saturated carboxylic acids and their esters creates conditions for the formation of compounds with antinociceptive activity, which was confirmed in vivo by experimental data acetic acid-induced writhing test and formalin inflammation model.
Permanent epidemiological monitoring of biosafety of the external environment, livestock buildings, manure, soil, and milk is an important but methodologically difficult problem of veterinary and sanitary control. Indication of infectious pathogens by classical methods of laboratory analysis can lead to incomplete and untimely diagnostics of zoonotic pathogens, especially in the case of adaptogenic transformation of prokaryotes under the influence of physicochemical and biological pressure of the ecotope of the habitat of the transient microbial association. At the same time, it is known that clinically healthy animals in a stable ecotope of habitat favorable for infectious pathology do not release zoonotic pathogens into the environment and livestock products. Biomarkers of sanitary well-being and the absence of pathogens of zooanthroponosis can be indigenous prokaryotes with probiotic activity, which exist only in the body of clinically healthy animals and are released into the external environment, where they also exhibit antagonistic potential against parasitocenoses of microbial origin. Such prokaryotic biomarkers of sanitary well-being of the habitat of productive animals include Mycobacterium vaccae and Aerococcus viridans. These are prokaryotes with probiotic potential and antagonistic activity against opportunistic microflora. At the same time, aerococci mainly live in the internal environment of the macroorganism in a state of physiological norm and are released from it during pathophysiological changes, and mycobacteria vaccae prevail in the external environment and belong to the saprophytic association of microbionts with transient abilities, that is, they survive in the internal environment of the macroorganism for a limited time. Therefore, these microbionts can be classified as sanitary indicative and, acting as biomarkers of infection well-being, they provide information on the state of the microbial landscape in the internal environment and external environment of the organism of productive animals
Вступ. Загальновідомо, що 1,2,4-триазол та його похідні часто використовують для створення перспективних біологічно активних молекул. Посилити сприятливий фармакологічний профіль даного гетероциклу дозволяють певні фармакофорні замісники. Практична реалізація зазначеної думки була втілена шляхом залучення до структури похідних 1,2,4-триазолу фармакофорного фрагменту у вигляді пара-метоксифенільного замісника та хімічно реакційноздатною тіольною групою, яка дозволяє збагачувати структуру цільових продуктів необхідними у фармакокінетичному сенсі замісниками. Додатковий вплив на ряд фізико-хімічних та фармакодинамічних параметрів досягався введенням метильного замісника до п’ятого положення гетероциклічної системи 1,2,4-триазолу, що дозволило підвищити практичну значимість кінцевих продуктів хімічного перетворення. Метою дослідження було проведення цілеспрямованого синтезу амідів 2-(5-метил-4-(4-метоксифеніл)-1,2,4-триазол-3-ілтіо)етанової кислоти та вивчення їх фізико-хімічних властивостей та фармакологічного потенціалу. Матеріали і методи. Синтез цільових продуктів здійснювався шляхом використання загальновідомих методів синтезу. З метою формування попереднього уявлення про безпеку та потенційну токсичність одержаних речовин використовувався in silico аналіз, який реалізовувався за допомогою програмного забезпечення T.E.S.T. Визначення ряду фізико-хімічних показників, які безпосередньо пов’язані з важливими фармакокінетичними параметрами, проводилось з використанням он-лайн платформи SwissADME. Результати. Встановлені практично значимі та зручні умови синтетичного процесу, які дозволяють здійснити формування структури 4-(пара-метоксифеніл)-5-метил-1,2,4-триазол-3-тіолу та амідів 2-(5-метил-4-(пара-метоксифеніл)-1,2,4-триазол-3-ілтіо)етанової кислоти. Сформовані in silico показники критеріїв гострої токсичності за допомогою програми T.E.S.T. демонструють факт приналежності одержаних сполук до 3 або 4 класів токсичності, що дозволяє визначати попередньо їх як помірнотоксичні або малотоксичні. Проявлення мутагенних властивостей серед досліджених за даним напрямком in silico речовин є неможливим, що може бути у майбутньому використано як додаткова перевага на користь подальших досліджень. Результати SwissADME аналізу демонструють досить сприятливий профіль фармакологічних показників як фармакокінетичного так і фармакодинамічного характеру. Висновки. Обґрунтовано, що 2-(5-Метил-4-(4-метоксифеніл)-1,2,4-триазол-3-ілтіо)ацет-аміди можна вважати практично-значимим джерелом створення біологічно активної субстанції.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.